Reductive sp 3 -sp 2 Coupling Reactions Enable Late-Stage Modification of Pharmaceuticals.

Late-stage derivatization of pharmaceutically relevant scaffolds relies on the availability of highly functional-group tolerant reactions. Reactions that increase the sp ³ character of molecules enable the pursuit of more selective and well-tolerated pharmaceuticals. Herein, we report the use of sp ³ -sp ² cross-electrophile reductive couplings to modify a generic ATP-competitive kinase inhibitor with a broad range of primary and secondary alkyl halide coupling partners.